As depicted in Supplementary Figure S3, we identified seventeen drugs that target TEK and eleven drugs that target CD40LG. Previous clinical trials have demonstrated the efficacy of one particular medication from the aforementioned list in treating open angle glaucoma or ocular hypertension (Brigell et al., 2022). This evidence concerns the gene TEK and open-angle glaucoma.